HRP20220144T1 - Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora - Google Patents
Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora Download PDFInfo
- Publication number
- HRP20220144T1 HRP20220144T1 HRP20220144TT HRP20220144T HRP20220144T1 HR P20220144 T1 HRP20220144 T1 HR P20220144T1 HR P20220144T T HRP20220144T T HR P20220144TT HR P20220144 T HRP20220144 T HR P20220144T HR P20220144 T1 HRP20220144 T1 HR P20220144T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- pyrazolo
- pyridin
- octan
- tetrahydro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 24
- 239000003112 inhibitor Substances 0.000 title claims 3
- 102000002689 Toll-like receptor Human genes 0.000 title 1
- 108020000411 Toll-like receptor Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 101100439665 Arabidopsis thaliana SWI2 gene Proteins 0.000 claims 35
- 229910052799 carbon Inorganic materials 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical group 0.000 claims 10
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- -1 8-oxa-3-azabicyclo[3.2.1]octanyl Chemical group 0.000 claims 6
- VCLQDVVELGHZMQ-UHFFFAOYSA-N bicyclo[2.2.2]octan-4-amine Chemical compound C1CC2CCC1(N)CC2 VCLQDVVELGHZMQ-UHFFFAOYSA-N 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- YPSPPJRTCRMQGD-UHFFFAOYSA-N morpholine-3-carboxamide Chemical compound NC(=O)C1COCCN1 YPSPPJRTCRMQGD-UHFFFAOYSA-N 0.000 claims 4
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims 3
- ZJQUYMSJJCOQDR-UHFFFAOYSA-N 2-(dimethylamino)-N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]acetamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CN(C)C)=O)C ZJQUYMSJJCOQDR-UHFFFAOYSA-N 0.000 claims 2
- ZQDYYNNLUWGZGP-UHFFFAOYSA-N 6-[4-[[3-methyl-5-(1,3,5-trimethylpyrazolo[4,3-d]pyrimidin-7-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-2-oxa-6-azaspiro[3.3]heptane Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)N1CC2(COC2)C1 ZQDYYNNLUWGZGP-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- DZZMUECMSYRUMS-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]oxetan-3-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC1COC1)C DZZMUECMSYRUMS-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- GLMGGJKMBDJDKY-UHFFFAOYSA-N (1-methylcyclopropyl) N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]carbamate Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(OC1(CC1)C)=O)C GLMGGJKMBDJDKY-UHFFFAOYSA-N 0.000 claims 1
- MVLRHACOUUDUCN-WWJCJQDFSA-N (2R,6R)-4-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-2,6-dimethylmorpholine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1C[C@H](O[C@@H](C1)C)C)C MVLRHACOUUDUCN-WWJCJQDFSA-N 0.000 claims 1
- MVLRHACOUUDUCN-PSTSRGLJSA-N (2S,6S)-4-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-2,6-dimethylmorpholine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1C[C@@H](O[C@H](C1)C)C)C MVLRHACOUUDUCN-PSTSRGLJSA-N 0.000 claims 1
- JEOGNLCMPZYSLO-DKLJTCSJSA-N (3R,4S)-1-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]pyrrolidine-3,4-diol Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1C[C@@H]([C@@H](C1)O)O)C JEOGNLCMPZYSLO-DKLJTCSJSA-N 0.000 claims 1
- ZJEWUUOXOSKENR-VDOPKETPSA-N (3S)-N-[4-[[5-(1-ethyl-6-methylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]morpholine-3-carboxamide Chemical compound C(C)N1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(=O)[C@H]1NCCOC1)C ZJEWUUOXOSKENR-VDOPKETPSA-N 0.000 claims 1
- JEOGNLCMPZYSLO-DMANWNPNSA-N (3S,4S)-1-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]pyrrolidine-3,4-diol Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1C[C@@H]([C@H](C1)O)O)C JEOGNLCMPZYSLO-DMANWNPNSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- GWYTYVPEELRELI-UHFFFAOYSA-N 1,3,5-trimethyl-7-[3-methyl-1-[(4-pyrrolidin-1-yl-1-bicyclo[2.2.2]octanyl)methyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]pyrazolo[4,3-d]pyrimidine Chemical compound CN1N=C(C=2N=C(N=C(C=21)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCCC1)C)C GWYTYVPEELRELI-UHFFFAOYSA-N 0.000 claims 1
- SDPCRIHZSWMXPK-UHFFFAOYSA-N 1,6-dimethyl-4-[3-methyl-1-[(4-pyrrolidin-1-yl-1-bicyclo[2.2.2]octanyl)methyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]pyrazolo[3,4-d]pyrimidine Chemical compound CN1N=CC=2C1=NC(=NC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCCC1)C SDPCRIHZSWMXPK-UHFFFAOYSA-N 0.000 claims 1
- YTBSAUXDZWAJEL-UHFFFAOYSA-N 1,6-dimethyl-4-[3-methyl-1-[(4-pyrrolidin-1-yl-2-oxabicyclo[2.2.2]octan-1-yl)methyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]pyrazolo[3,4-b]pyridine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12OCC(CC1)(CC2)N1CCCC1)C YTBSAUXDZWAJEL-UHFFFAOYSA-N 0.000 claims 1
- FBLZDTKUQLWKBS-UHFFFAOYSA-N 1-(1-bicyclo[2.2.2]octanyl)pyrrolidine Chemical compound C12(CCC(CC1)CC2)N2CCCC2 FBLZDTKUQLWKBS-UHFFFAOYSA-N 0.000 claims 1
- VQOZGTLRERPTED-UHFFFAOYSA-N 1-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-4-methylpiperazin-2-one Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1C(CN(CC1)C)=O)C VQOZGTLRERPTED-UHFFFAOYSA-N 0.000 claims 1
- KYHJYPOONOMZHS-UHFFFAOYSA-N 1-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]azetidin-3-ol Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CC(C1)O)C KYHJYPOONOMZHS-UHFFFAOYSA-N 0.000 claims 1
- YEQFIJQKCMQUES-UHFFFAOYSA-N 1-[[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]amino]-2-methylpropan-2-ol Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NCC(C)(O)C)C YEQFIJQKCMQUES-UHFFFAOYSA-N 0.000 claims 1
- VDYUPDDZJAKHIU-UHFFFAOYSA-N 1-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N,N-dimethyl-2-oxabicyclo[2.2.2]octan-4-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12OCC(CC1)(CC2)N(C)C)C VDYUPDDZJAKHIU-UHFFFAOYSA-N 0.000 claims 1
- JNAOKAXFZFQQHH-UHFFFAOYSA-N 1-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-(2-methoxyethyl)-2-oxabicyclo[2.2.2]octan-4-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12OCC(CC1)(CC2)NCCOC)C JNAOKAXFZFQQHH-UHFFFAOYSA-N 0.000 claims 1
- DITZKDMEWPZWEB-UHFFFAOYSA-N 2-[[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]amino]-1-piperidin-1-ylethanone Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NCC(=O)N1CCCCC1)C DITZKDMEWPZWEB-UHFFFAOYSA-N 0.000 claims 1
- RGDHEVHSEYQVPF-UHFFFAOYSA-N 2-[[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]amino]-N,N-dimethylacetamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NCC(=O)N(C)C)C RGDHEVHSEYQVPF-UHFFFAOYSA-N 0.000 claims 1
- ZJQUYMSJJCOQDR-LIJFRPJRSA-N 2-[bis(trideuteriomethyl)amino]-N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]acetamide Chemical compound [2H]C([2H])([2H])N(CC(=O)NC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=C2C(=NC(=C1)C)N(N=C2)C)C)C([2H])([2H])[2H] ZJQUYMSJJCOQDR-LIJFRPJRSA-N 0.000 claims 1
- DKENMMZXYLOONY-UHFFFAOYSA-N 2-methyl-4-[3-methyl-1-[(4-pyrrolidin-1-yl-1-bicyclo[2.2.2]octanyl)methyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1,7-naphthyridine Chemical compound CC1=NC2=CN=CC=C2C(=C1)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCCC1 DKENMMZXYLOONY-UHFFFAOYSA-N 0.000 claims 1
- QBAXNPYOWNTOGS-UHFFFAOYSA-N 3-(dimethylamino)-N-[4-[[3-methyl-5-(1,3,5-trimethylpyrazolo[4,3-d]pyrimidin-7-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]propanamide Chemical compound CN(CCC(=O)NC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C=1C2=C(N=C(N=1)C)C(=NN2C)C)C)C QBAXNPYOWNTOGS-UHFFFAOYSA-N 0.000 claims 1
- FAPUHGMBJWVSJV-UHFFFAOYSA-N 3-methyl-5-(2-phenylpyridin-4-yl)-1-[(4-pyrrolidin-1-yl-1-bicyclo[2.2.2]octanyl)methyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine Chemical compound CC1=NN(C2=C1CN(CC2)C1=CC(=NC=C1)C1=CC=CC=C1)CC12CCC(CC1)(CC2)N1CCCC1 FAPUHGMBJWVSJV-UHFFFAOYSA-N 0.000 claims 1
- GNJFKVPYALONCI-UHFFFAOYSA-N 4-[1-[(4-amino-1-bicyclo[2.2.2]octanyl)methyl]-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1-methylpyrazolo[3,4-d]pyrimidin-6-amine Chemical compound NC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=C2C(=NC(=N1)N)N(N=C2)C)C GNJFKVPYALONCI-UHFFFAOYSA-N 0.000 claims 1
- WADGAKPPIQKNCB-UHFFFAOYSA-N 4-[1-[(4-amino-1-bicyclo[2.2.2]octanyl)methyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1-methylpyrazolo[3,4-d]pyrimidin-6-amine Chemical compound NC12CCC(CC1)(CC2)CN1N=CC=2CN(CCC=21)C1=C2C(=NC(=N1)N)N(N=C2)C WADGAKPPIQKNCB-UHFFFAOYSA-N 0.000 claims 1
- WVCNTBJTQVTYNP-UHFFFAOYSA-N 4-[1-[(4-imidazol-1-yl-1-bicyclo[2.2.2]octanyl)methyl]-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1,6-dimethylpyrazolo[3,4-b]pyridine Chemical compound N1(C=NC=C1)C12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=C2C(=NC(=C1)C)N(N=C2)C)C WVCNTBJTQVTYNP-UHFFFAOYSA-N 0.000 claims 1
- XQVGWDKLVOOQCK-UHFFFAOYSA-N 4-[2-[(4-amino-1-bicyclo[2.2.2]octanyl)methyl]-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1-methylpyrazolo[3,4-d]pyrimidin-6-amine Chemical compound NC12CCC(CC1)(CC2)CN1N=C2C(CN(CC2)C2=C3C(=NC(=N2)N)N(N=C3)C)=C1C XQVGWDKLVOOQCK-UHFFFAOYSA-N 0.000 claims 1
- GRNXVRVRLWDSFK-UHFFFAOYSA-N 4-[2-[(4-amino-1-bicyclo[2.2.2]octanyl)methyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1-methylpyrazolo[3,4-d]pyrimidin-6-amine Chemical compound Cn1ncc2c(nc(N)nc12)N1CCc2nn(CC34CCC(N)(CC3)CC4)cc2C1 GRNXVRVRLWDSFK-UHFFFAOYSA-N 0.000 claims 1
- VWLGOCYVCMYVAH-UHFFFAOYSA-N 4-[2-[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]ethyl]bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CCC12CCC(CC1)(CC2)N)C VWLGOCYVCMYVAH-UHFFFAOYSA-N 0.000 claims 1
- AZAMOYKQMRIGAB-UHFFFAOYSA-N 4-[4-[1-[(4-amino-1-bicyclo[2.2.2]octanyl)methyl]-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]pyridin-2-yl]benzonitrile Chemical compound NC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=CC(=NC=C1)C1=CC=C(C#N)C=C1)C AZAMOYKQMRIGAB-UHFFFAOYSA-N 0.000 claims 1
- CQSXCOJVRDNCPQ-UHFFFAOYSA-N 4-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-1-methylpiperazin-2-one Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CC(N(CC1)C)=O)C CQSXCOJVRDNCPQ-UHFFFAOYSA-N 0.000 claims 1
- ZRWPIUMXTMSSQC-UHFFFAOYSA-N 4-[4-[[5-(1,6-dimethylpyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]morpholine Chemical compound CN1N=CC=2C1=NC(=NC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCOCC1)C ZRWPIUMXTMSSQC-UHFFFAOYSA-N 0.000 claims 1
- GMHQSMCIZDKVFN-RKAHMFOGSA-N 4-[[3-methyl-5-(1,3,5-trimethylpyrazolo[4,3-d]pyrimidin-7-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N,N-bis(trideuteriomethyl)bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)N(C([2H])([2H])[2H])C([2H])([2H])[2H] GMHQSMCIZDKVFN-RKAHMFOGSA-N 0.000 claims 1
- FBKBQRYGXXZVKV-UHFFFAOYSA-N 4-[[3-methyl-5-(1,3,5-trimethylpyrazolo[4,3-d]pyrimidin-7-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-(oxetan-3-ylmethyl)bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NCC1COC1 FBKBQRYGXXZVKV-UHFFFAOYSA-N 0.000 claims 1
- LUVKRBBSLTVVCQ-UHFFFAOYSA-N 4-[[3-methyl-5-(1,3,5-trimethylpyrazolo[4,3-d]pyrimidin-7-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)N LUVKRBBSLTVVCQ-UHFFFAOYSA-N 0.000 claims 1
- RSNHEPBZVFDERR-UHFFFAOYSA-N 4-[[3-methyl-5-(1H-pyrazolo[3,4-b]pyridin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NN(C2=C1CN(CC2)C1=C2C(=NC=C1)NN=C2)CC12CCC(CC1)(CC2)N RSNHEPBZVFDERR-UHFFFAOYSA-N 0.000 claims 1
- FQXZADGHUZGILZ-UHFFFAOYSA-N 4-[[3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NN(C2=C1CN(CC2)C1=CC(=NC2=CN=CC=C12)C)CC12CCC(CC1)(CC2)N FQXZADGHUZGILZ-UHFFFAOYSA-N 0.000 claims 1
- JBRBABSSFICXDF-UHFFFAOYSA-N 4-[[3-methyl-5-(2-methyl-6-phenylpyridin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NN(C2=C1CN(CC2)C1=CC(=NC(=C1)C1=CC=CC=C1)C)CC12CCC(CC1)(CC2)N JBRBABSSFICXDF-UHFFFAOYSA-N 0.000 claims 1
- KUFJILBOJUHSOR-UHFFFAOYSA-N 4-[[3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)NC=C2)CC12CCC(CC1)(CC2)N KUFJILBOJUHSOR-UHFFFAOYSA-N 0.000 claims 1
- ALUJZNDUAYUECU-UHFFFAOYSA-N 4-[[3-methyl-5-(2-phenylpyridin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NN(C2=C1CN(CC2)C1=CC(=NC=C1)C1=CC=CC=C1)CC12CCC(CC1)(CC2)N ALUJZNDUAYUECU-UHFFFAOYSA-N 0.000 claims 1
- ZWVCZRQPYARBEI-UHFFFAOYSA-N 4-[[3-methyl-5-(6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NN(C2=C1CN(CC2)C1=C2C(=NC(=C1)C)NN=C2)CC12CCC(CC1)(CC2)N ZWVCZRQPYARBEI-UHFFFAOYSA-N 0.000 claims 1
- YAUFOYYLQGGMAQ-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N,N-bis(2-ethoxyethyl)bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N(CCOCC)CCOCC)C YAUFOYYLQGGMAQ-UHFFFAOYSA-N 0.000 claims 1
- MXAVIZCIWRHZRE-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N,N-bis(2-methoxyethyl)bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N(CCOC)CCOC)C MXAVIZCIWRHZRE-UHFFFAOYSA-N 0.000 claims 1
- ZOIOIBRNCQVPHU-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N,N-dimethylbicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N(C)C)C ZOIOIBRNCQVPHU-UHFFFAOYSA-N 0.000 claims 1
- BROBFARKXSNHAN-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-(1-methoxypropan-2-yl)bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(COC)C)C BROBFARKXSNHAN-UHFFFAOYSA-N 0.000 claims 1
- LKRNKASDLWUEHJ-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-(2-ethoxyethyl)bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NCCOCC)C LKRNKASDLWUEHJ-UHFFFAOYSA-N 0.000 claims 1
- BIATUTYFISRPTJ-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-(2-methoxy-2-methylpropyl)bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NCC(C)(C)OC)C BIATUTYFISRPTJ-UHFFFAOYSA-N 0.000 claims 1
- ANRJLNKBQDKPQU-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-(2-methoxyethyl)-N-methylbicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N(C)CCOC)C ANRJLNKBQDKPQU-UHFFFAOYSA-N 0.000 claims 1
- IDCLYTLADAHRHB-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-(2-methoxyethyl)bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NCCOC)C IDCLYTLADAHRHB-UHFFFAOYSA-N 0.000 claims 1
- XTGDTXIIQAJLGO-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-ethyl-N-methylbicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N(C)CC)C XTGDTXIIQAJLGO-UHFFFAOYSA-N 0.000 claims 1
- WWUZQMKWJDEHQO-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-ethylbicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NCC)C WWUZQMKWJDEHQO-UHFFFAOYSA-N 0.000 claims 1
- HYNDDXACQHHUHD-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-methylbicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC)C HYNDDXACQHHUHD-UHFFFAOYSA-N 0.000 claims 1
- AJGPPIBTYBYMED-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-propan-2-ylbicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(C)C)C AJGPPIBTYBYMED-UHFFFAOYSA-N 0.000 claims 1
- OPISDWAVYCGJQH-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.1]heptan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(C2)N)C OPISDWAVYCGJQH-UHFFFAOYSA-N 0.000 claims 1
- XGRLHCCHDAZYII-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N)C XGRLHCCHDAZYII-UHFFFAOYSA-N 0.000 claims 1
- ATTKSCANVMYECQ-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-ol Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)O)C ATTKSCANVMYECQ-UHFFFAOYSA-N 0.000 claims 1
- KZQFJYDFVPUYMZ-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-7,7-dimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(C(C1)(C)C)N(N=C2)CC12CCC(CC1)(CC2)N)C KZQFJYDFVPUYMZ-UHFFFAOYSA-N 0.000 claims 1
- HYIYYNQLLOGDER-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-7,7-dimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-2-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC=2C(C(C1)(C)C)=NN(C=2)CC12CCC(CC1)(CC2)N)C HYIYYNQLLOGDER-UHFFFAOYSA-N 0.000 claims 1
- VNYWWNZBTDCSOK-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=NC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N)C VNYWWNZBTDCSOK-UHFFFAOYSA-N 0.000 claims 1
- QGIBKNMEYFXPES-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrrolo[2,3-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CN1C=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N)C QGIBKNMEYFXPES-UHFFFAOYSA-N 0.000 claims 1
- NQHPMSIMTFEEHW-UHFFFAOYSA-N 4-[[5-(1-ethyl-6-methylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound C(C)N1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N)C NQHPMSIMTFEEHW-UHFFFAOYSA-N 0.000 claims 1
- NQFOPAUKBRZOLB-UHFFFAOYSA-N 4-[[5-(2,8-dimethyl-1,7-naphthyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NC2=C(N=CC=C2C(=C1)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N)C NQFOPAUKBRZOLB-UHFFFAOYSA-N 0.000 claims 1
- LJDGNLXMBFLTSX-UHFFFAOYSA-N 4-[[5-[1-[(4-methoxyphenyl)methyl]-6-methylpyrazolo[3,4-b]pyridin-4-yl]-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound COC1=CC=C(CN2N=CC=3C2=NC(=CC=3N2CC3=C(CC2)N(N=C3C)CC23CCC(CC2)(CC3)N)C)C=C1 LJDGNLXMBFLTSX-UHFFFAOYSA-N 0.000 claims 1
- GVLJFTHJYVRHCI-UHFFFAOYSA-N 4-[[5-[2-(2-fluoro-4-methylphenyl)pyridin-4-yl]-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound FC1=C(C=CC(=C1)C)C1=NC=CC(=C1)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N GVLJFTHJYVRHCI-UHFFFAOYSA-N 0.000 claims 1
- HFPMQKVVANHFGO-UHFFFAOYSA-N 4-[[5-[6-(4-fluorophenyl)-1-methylpyrazolo[3,4-d]pyrimidin-4-yl]-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound FC1=CC=C(C=C1)C1=NC(=C2C(=N1)N(N=C2)C)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N HFPMQKVVANHFGO-UHFFFAOYSA-N 0.000 claims 1
- RCPFKNIWFCVDLQ-UHFFFAOYSA-N 4-oxa-3-azabicyclo[3.2.1]octane Chemical group C1C2CCC1ONC2 RCPFKNIWFCVDLQ-UHFFFAOYSA-N 0.000 claims 1
- IFRQSMKYDUYYKE-UHFFFAOYSA-N 6-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-2-oxa-6-azaspiro[3.3]heptane Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CC2(COC2)C1)C IFRQSMKYDUYYKE-UHFFFAOYSA-N 0.000 claims 1
- BDMTUMICKOOWGR-UHFFFAOYSA-N 6-methyl-4-[3-methyl-1-[(4-pyrrolidin-1-yl-1-bicyclo[2.2.2]octanyl)methyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1H-pyrazolo[3,4-d]pyrimidine Chemical compound CC1=NC(=C2C(=N1)NN=C2)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCCC1 BDMTUMICKOOWGR-UHFFFAOYSA-N 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- CSQJLZFPSBFTGQ-UHFFFAOYSA-N C(C)NC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=CC(=NC=C1)C1=CC=CC=C1)C Chemical compound C(C)NC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=CC(=NC=C1)C1=CC=CC=C1)C CSQJLZFPSBFTGQ-UHFFFAOYSA-N 0.000 claims 1
- ACOZHGNZPOVLRY-UHFFFAOYSA-N C(C)NCC(=O)NC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C=1C2=C(N=C(N=1)C)C(=NN2C)C)C Chemical compound C(C)NCC(=O)NC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C=1C2=C(N=C(N=1)C)C(=NN2C)C)C ACOZHGNZPOVLRY-UHFFFAOYSA-N 0.000 claims 1
- YCUYKOAQDXCHFP-UHFFFAOYSA-N C1(CCC1)N(C12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C=1C2=C(N=C(N=1)C)C(=NN2C)C)C)C1CCC1 Chemical compound C1(CCC1)N(C12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C=1C2=C(N=C(N=1)C)C(=NN2C)C)C)C1CCC1 YCUYKOAQDXCHFP-UHFFFAOYSA-N 0.000 claims 1
- MJVMMMBHEVUKMT-UHFFFAOYSA-N CC1=NC(=C2C(=N1)NN=C2)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCCCC1 Chemical compound CC1=NC(=C2C(=N1)NN=C2)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCCCC1 MJVMMMBHEVUKMT-UHFFFAOYSA-N 0.000 claims 1
- HEOGAITZCCZUPL-UHFFFAOYSA-N CC1=NN(C2=C1CN(CC2)C1=C2C(=NC(=N1)C)NN=C2)CC12CCC(CC1)(CC2)N1CCOCC1 Chemical compound CC1=NN(C2=C1CN(CC2)C1=C2C(=NC(=N1)C)NN=C2)CC12CCC(CC1)(CC2)N1CCOCC1 HEOGAITZCCZUPL-UHFFFAOYSA-N 0.000 claims 1
- UTPIRVJJLPSASP-UHFFFAOYSA-N CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NC(=O)C1CNC1 Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NC(=O)C1CNC1 UTPIRVJJLPSASP-UHFFFAOYSA-N 0.000 claims 1
- LIPWAGDFQCCAFM-SAVAPUMLSA-N CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NC(=O)[C@@H]1CNCCO1 Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NC(=O)[C@@H]1CNCCO1 LIPWAGDFQCCAFM-SAVAPUMLSA-N 0.000 claims 1
- FMSJNNSUCNZKKS-JOLTYGGCSA-N CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NC(=O)[C@@H]1NCCOC1 Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NC(=O)[C@@H]1NCCOC1 FMSJNNSUCNZKKS-JOLTYGGCSA-N 0.000 claims 1
- LIPWAGDFQCCAFM-XPCYEKABSA-N CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NC(=O)[C@H]1CNCCO1 Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NC(=O)[C@H]1CNCCO1 LIPWAGDFQCCAFM-XPCYEKABSA-N 0.000 claims 1
- FMSJNNSUCNZKKS-LWJVVSBASA-N CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NC(=O)[C@H]1NCCOC1 Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NC(=O)[C@H]1NCCOC1 FMSJNNSUCNZKKS-LWJVVSBASA-N 0.000 claims 1
- XXQKTRHMEBDWTR-UHFFFAOYSA-N CC1=NOC2=NC(=NC(=C21)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCOCC1)C Chemical compound CC1=NOC2=NC(=NC(=C21)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCOCC1)C XXQKTRHMEBDWTR-UHFFFAOYSA-N 0.000 claims 1
- DLUSQJSMZFZQSL-UHFFFAOYSA-N CC=1N(N=C2C=1CN(CC2)C1=C2C(=NC=C1)NN=C2)CC12CCC(CC1)(CC2)N Chemical compound CC=1N(N=C2C=1CN(CC2)C1=C2C(=NC=C1)NN=C2)CC12CCC(CC1)(CC2)N DLUSQJSMZFZQSL-UHFFFAOYSA-N 0.000 claims 1
- YAIVMAONVOQDND-UHFFFAOYSA-N CN1N=C(C=2N=C(N=C(C=21)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCCCC1)C)C Chemical compound CN1N=C(C=2N=C(N=C(C=21)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCCCC1)C)C YAIVMAONVOQDND-UHFFFAOYSA-N 0.000 claims 1
- ZTHOYBGKKJCLKP-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C(F)(F)F)CC12CCC(CC1)(CC2)N)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C(F)(F)F)CC12CCC(CC1)(CC2)N)C ZTHOYBGKKJCLKP-UHFFFAOYSA-N 0.000 claims 1
- WPDFYCKYECWQAO-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N(C)C(C)C)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N(C)C(C)C)C WPDFYCKYECWQAO-UHFFFAOYSA-N 0.000 claims 1
- FTBFHSBOOZZAAM-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCOCC1)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCOCC1)C FTBFHSBOOZZAAM-UHFFFAOYSA-N 0.000 claims 1
- IPODTNFKXKRZFZ-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCS(CC1)(=O)=O)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCS(CC1)(=O)=O)C IPODTNFKXKRZFZ-UHFFFAOYSA-N 0.000 claims 1
- MVLRHACOUUDUCN-XICVLRSMSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1C[C@@H](O[C@@H](C1)C)C)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1C[C@@H](O[C@@H](C1)C)C)C MVLRHACOUUDUCN-XICVLRSMSA-N 0.000 claims 1
- ZYQOWTOTWVFCPE-KUKIJGICSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1C[C@H]2CC[C@@H](C1)O2)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1C[C@H]2CC[C@@H](C1)O2)C ZYQOWTOTWVFCPE-KUKIJGICSA-N 0.000 claims 1
- YJTMIOIWDMKSAT-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(=O)C1CNCCO1)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(=O)C1CNCCO1)C YJTMIOIWDMKSAT-UHFFFAOYSA-N 0.000 claims 1
- SGYICBKQCSQCED-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CCN(C)C)=O)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CCN(C)C)=O)C SGYICBKQCSQCED-UHFFFAOYSA-N 0.000 claims 1
- GGWUHPSLNIDLHZ-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CCNC)=O)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CCNC)=O)C GGWUHPSLNIDLHZ-UHFFFAOYSA-N 0.000 claims 1
- UVAMCUMFZVRLDC-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CN(C(C)=O)C)=O)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CN(C(C)=O)C)=O)C UVAMCUMFZVRLDC-UHFFFAOYSA-N 0.000 claims 1
- AIGIIFNVEMXTRT-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CN1CC(C1)F)=O)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CN1CC(C1)F)=O)C AIGIIFNVEMXTRT-UHFFFAOYSA-N 0.000 claims 1
- IEYDUBRYPJGWPP-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CO)C)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CO)C)C IEYDUBRYPJGWPP-UHFFFAOYSA-N 0.000 claims 1
- MHUOWLJPSJOIRW-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NCC(=O)N1CCCC1)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NCC(=O)N1CCCC1)C MHUOWLJPSJOIRW-UHFFFAOYSA-N 0.000 claims 1
- VCBCBCDPVGHRFT-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12OCC(CC1)(CC2)N)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12OCC(CC1)(CC2)N)C VCBCBCDPVGHRFT-UHFFFAOYSA-N 0.000 claims 1
- QKXNNOFPUUVOHA-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12OCC(CC1)(CC2)N1CCCCC1)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12OCC(CC1)(CC2)N1CCCCC1)C QKXNNOFPUUVOHA-UHFFFAOYSA-N 0.000 claims 1
- HBFXBBDIZIXQJS-UHFFFAOYSA-N CN1N=CC=2C1=NC(=CC=2N1CC=2C(CC1)=NN(C=2C)CC12CC(C1)(C2)N)C Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC=2C(CC1)=NN(C=2C)CC12CC(C1)(C2)N)C HBFXBBDIZIXQJS-UHFFFAOYSA-N 0.000 claims 1
- KYEGHBUGXTZCIF-UHFFFAOYSA-N CN1N=CC=2C1=NC(=NC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCCCC1)C Chemical compound CN1N=CC=2C1=NC(=NC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N1CCCCC1)C KYEGHBUGXTZCIF-UHFFFAOYSA-N 0.000 claims 1
- XHQSZEQRXLSPHM-UHFFFAOYSA-N ClC=1N=C(C2=C(N=1)C=NN2C)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N Chemical compound ClC=1N=C(C2=C(N=1)C=NN2C)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N XHQSZEQRXLSPHM-UHFFFAOYSA-N 0.000 claims 1
- DTOZZXNKMPAAIQ-UHFFFAOYSA-N ClC=1N=C(C2=C(N=1)COC2)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N Chemical compound ClC=1N=C(C2=C(N=1)COC2)N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N DTOZZXNKMPAAIQ-UHFFFAOYSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- BDOGDBITBOXKHW-UHFFFAOYSA-N N-(2,2-difluoroethyl)-4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound FC(CNC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=C2C(=NC(=C1)C)N(N=C2)C)C)F BDOGDBITBOXKHW-UHFFFAOYSA-N 0.000 claims 1
- GLWIFSDFJOAMCU-UHFFFAOYSA-N N-(2-methoxyethyl)-4-[[3-methyl-5-(1,3,5-trimethylpyrazolo[4,3-d]pyrimidin-7-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound COCCNC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C=1C2=C(N=C(N=1)C)C(=NN2C)C)C GLWIFSDFJOAMCU-UHFFFAOYSA-N 0.000 claims 1
- ZEJHEINTSICIPV-UHFFFAOYSA-N N-(2-methoxyethyl)-4-[[3-methyl-5-(2-phenylpyridin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound COCCNC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=CC(=NC=C1)C1=CC=CC=C1)C ZEJHEINTSICIPV-UHFFFAOYSA-N 0.000 claims 1
- JGVIYGSZQGWXOA-UHFFFAOYSA-N N-(cyclobutylmethyl)-1-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-2-oxabicyclo[2.2.2]octan-4-amine Chemical compound C1(CCC1)CNC12COC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=C2C(=NC(=C1)C)N(N=C2)C)C JGVIYGSZQGWXOA-UHFFFAOYSA-N 0.000 claims 1
- MWARMZMYJKAIDP-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-2-(3-hydroxyazetidin-1-yl)acetamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CN1CC(C1)O)=O)C MWARMZMYJKAIDP-UHFFFAOYSA-N 0.000 claims 1
- OPVKFGSBWZTAPU-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-2-(ethylamino)acetamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CNCC)=O)C OPVKFGSBWZTAPU-UHFFFAOYSA-N 0.000 claims 1
- ILVXEEZDBQNWAF-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-2-(methylamino)acetamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CNC)=O)C ILVXEEZDBQNWAF-UHFFFAOYSA-N 0.000 claims 1
- DPBHELMHVHQEEY-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-2-[ethyl(methyl)amino]acetamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CN(C)CC)=O)C DPBHELMHVHQEEY-UHFFFAOYSA-N 0.000 claims 1
- XSWOGMDBWWCZAC-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-2-[methyl(methylsulfonyl)amino]acetamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CN(S(=O)(=O)C)C)=O)C XSWOGMDBWWCZAC-UHFFFAOYSA-N 0.000 claims 1
- JGWBAAMEJAJUEK-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-2-hydroxyacetamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CO)=O)C JGWBAAMEJAJUEK-UHFFFAOYSA-N 0.000 claims 1
- NEAISYLKENOCHT-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-2-pyrrolidin-1-ylacetamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CN1CCCC1)=O)C NEAISYLKENOCHT-UHFFFAOYSA-N 0.000 claims 1
- GDIQKELNBYAZFY-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-3-(ethylamino)propanamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(CCNCC)=O)C GDIQKELNBYAZFY-UHFFFAOYSA-N 0.000 claims 1
- AMLKKRULTSSTSX-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-4-methylmorpholine-3-carboxamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(=O)C1N(CCOC1)C)C AMLKKRULTSSTSX-UHFFFAOYSA-N 0.000 claims 1
- IKVABWKYFSVXON-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-N-methyloxetan-3-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N(C1COC1)C)C IKVABWKYFSVXON-UHFFFAOYSA-N 0.000 claims 1
- FJTJLIWQEFENKJ-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]acetamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(C)=O)C FJTJLIWQEFENKJ-UHFFFAOYSA-N 0.000 claims 1
- MYEVQOFAHCJEMS-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]azetidine-3-carboxamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(=O)C1CNC1)C MYEVQOFAHCJEMS-UHFFFAOYSA-N 0.000 claims 1
- NNDQLYPXFXEZKL-UHFFFAOYSA-N N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]methanesulfonamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NS(=O)(=O)C)C NNDQLYPXFXEZKL-UHFFFAOYSA-N 0.000 claims 1
- IMTNJWYSYNXESQ-UHFFFAOYSA-N N-cyclobutyl-1-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-2-oxabicyclo[2.2.2]octan-4-amine Chemical compound C1(CCC1)NC12COC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=C2C(=NC(=C1)C)N(N=C2)C)C IMTNJWYSYNXESQ-UHFFFAOYSA-N 0.000 claims 1
- CPWSJCANOVXJPJ-UHFFFAOYSA-N N-cyclobutyl-4-[[3-methyl-5-(1,3,5-trimethylpyrazolo[4,3-d]pyrimidin-7-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound C1(CCC1)NC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C=1C2=C(N=C(N=1)C)C(=NN2C)C)C CPWSJCANOVXJPJ-UHFFFAOYSA-N 0.000 claims 1
- LMCFHXNQDXLVTG-UHFFFAOYSA-N N-cyclobutyl-4-[[3-methyl-5-(2-phenylpyridin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound C1(CCC1)NC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=CC(=NC=C1)C1=CC=CC=C1)C LMCFHXNQDXLVTG-UHFFFAOYSA-N 0.000 claims 1
- JJBCBCGVGVFDRW-UHFFFAOYSA-N N-cyclobutyl-4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-N-methylbicyclo[2.2.2]octan-1-amine Chemical compound C1(CCC1)N(C12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=C2C(=NC(=C1)C)N(N=C2)C)C)C JJBCBCGVGVFDRW-UHFFFAOYSA-N 0.000 claims 1
- KDSRTNGJPMODDW-UHFFFAOYSA-N N-cyclobutyl-4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound C1(CCC1)NC12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=C2C(=NC(=C1)C)N(N=C2)C)C KDSRTNGJPMODDW-UHFFFAOYSA-N 0.000 claims 1
- DIPDVMHTIJJOID-UHFFFAOYSA-N N1(CCC1)C12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=C2C(=NC(=C1)C)N(N=C2)C)C Chemical compound N1(CCC1)C12CCC(CC1)(CC2)CN1N=C(C=2CN(CCC=21)C1=C2C(=NC(=C1)C)N(N=C2)C)C DIPDVMHTIJJOID-UHFFFAOYSA-N 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- KCXQGDQXSDDWLD-UHFFFAOYSA-N [3-[[[4-[[3-methyl-5-(1,3,5-trimethylpyrazolo[4,3-d]pyrimidin-7-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]amino]methyl]oxetan-3-yl]methanol Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)C(=NN2C)C)CC12CCC(CC1)(CC2)NCC1(COC1)CO KCXQGDQXSDDWLD-UHFFFAOYSA-N 0.000 claims 1
- IROXHMNBINMKJN-UHFFFAOYSA-N [3-[[[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]amino]methyl]oxetan-3-yl]methanol Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NCC1(COC1)CO)C IROXHMNBINMKJN-UHFFFAOYSA-N 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000000078 anti-malarial effect Effects 0.000 claims 1
- 230000003356 anti-rheumatic effect Effects 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 208000002557 hidradenitis Diseases 0.000 claims 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000003270 steroid hormone Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- MARHQPFPANQVBB-UHFFFAOYSA-N tert-butyl N-[4-[[3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]carbamate Chemical compound CC1=NN(C2=C1CN(CC2)C1=CC(=NC2=CN=CC=C12)C)CC12CCC(CC1)(CC2)NC(OC(C)(C)C)=O MARHQPFPANQVBB-UHFFFAOYSA-N 0.000 claims 1
- JGSMIIVIUJTVJJ-UHFFFAOYSA-N tert-butyl N-[4-[[3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]carbamate Chemical compound CC1=NN(C2=C1CN(CC2)C=1C2=C(N=C(N=1)C)NC=C2)CC12CCC(CC1)(CC2)NC(OC(C)(C)C)=O JGSMIIVIUJTVJJ-UHFFFAOYSA-N 0.000 claims 1
- YHNOZKVQKMNEEV-UHFFFAOYSA-N tert-butyl N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.1]heptanyl]carbamate Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(C2)NC(OC(C)(C)C)=O)C YHNOZKVQKMNEEV-UHFFFAOYSA-N 0.000 claims 1
- WQXBIXLREDQSEJ-UHFFFAOYSA-N tert-butyl N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]-N-methylcarbamate Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N(C(OC(C)(C)C)=O)C)C WQXBIXLREDQSEJ-UHFFFAOYSA-N 0.000 claims 1
- YXMFNTUFLZGCHF-UHFFFAOYSA-N tert-butyl N-[4-[[5-(1-ethyl-6-methylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]carbamate Chemical compound C(C)N1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(OC(C)(C)C)=O)C YXMFNTUFLZGCHF-UHFFFAOYSA-N 0.000 claims 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (17)
1. Spoj, naznačen time, da ima strukturu s Formulom (A) ili njegova farmaceutski prihvatljiva sol:
[image]
pri čemu:
RA je
[image]
[image]
[image]
L je -CH2- ili -CH2CH2-;
Y1 je -CH2- ili -CH2CH2-;
Y2 je -CH2- ili -CH2CH2-;
Y3 je -CH2- , -XCH2- ili -CH2X-;
X je -CH2- ili O;
R1 je -NHC(=O)R6, -NHC(=O)(CH2)nR6, -NH(CH2)nC(=O)R6, -NHC(=O)(CH2)mNHR5, -NHC(=O)(CH2)mN(R5)2, -NHC(=O)(CHR9)mNHR5, -NHC(=O)(CH2)mNH2, -NHC(=O)(CH2)nOR9, -NHC(=O)OR9, -NH(CH2)mC(=O)N(R5)2, -NH(CHR9)nC(=O)R6, NHC(=O)(CHR9)nR6, -NHC(=O)(CHR9)nN(R8)2, -NHC(=O)(CHR9)nNHR8, -NH(CHR9)nC(=O)N(R8)2, -NH(CHR9)mC(=O)R6, -NHR6, -NR5R6, -NH2, -N(R5)2, -NHR5, -NHR8, -N(R6R8), -NH(C(R9)2)nR10, -NR9C(=O)OR11, -NH(CH2)nR6, -NH(CHR9)nR6, -N(R6)2, -NHC(=O)(CH2)nN(CD3)2, -NH(CHR9)nCH2OR9, -NHCH2(CHR9)nOR9, -NH(CHR9)nOR9, -NR9(CH2)nOR9, -NHCH2(C(R9)2)nOR9, -OR9, -NR9C(=O)R5, -NR9C(=O)(CH2)nR5, -NR9C(=O)OR5, -NHS(=O)2R5, -NHC(=O)(CH2)nNR9C(=O)R5, -NHC(=O)(CH2)nNR9S(=O)2R5,
[image]
[image]
8-oksa-3-azabiciklo[3.2.1]oktanil, 5-6-eročlani heteroaril koji ima 1 do 3 člana prstena neovisno odabrana između N, O i S, ili 4-6-eročlanog heterocikloalkila koji ima 1 do 2 člana prstena neovisno odabrana između N, NH, NR16 i O koji je nesupstituiran ili je supstituiran s 1-2 skupine R7;
R2 je H, C1-C6alkil, C1-C6haloalkil ili C1-C6alkil supstituiran s 1-2 skupine R15;
R3 je H, C1-C6alkil, -CD3 ili benzil supstituiran s 1-2 skupine R10;
R4 je H, NH2, C1-C6alkil, halogen ili fenil supstituiran s 0-2 skupine R18;
svaki R5 je neovisno odabran između C1-C6alkila, -CD3 i -(CH2)nOR9;
R6 je C3-C6cikloalkil, oksa-3-azabiciklo[3.2.1]oktan ili 4-6-eročlani heterocikloalkil koji ima 1 do 2 člana prstena neovisno odabrana između N, NH, NR16 i O koji je nesupstituiran ili je supstituiran s 1-2 skupine R12;
svaki R7 je neovisno odabran između C1-C6alkila, halogena, hidroksila, okso i C1-C6alkila supstituiranog s 1 do 3 -OH;
svaki R8 je neovisno odabran između C1-C6haloalkila, -(C(R9)2)nOR9 i C1-C6alkila supstituiranog s 1 do 3 -OH;
svaki R9 je neovisno odabran između H i C1-C6alkila;
R10 je C1-C6alkoksi ili C3-C6cikloalkil;
R11 je C3-C6cikloalkil koji je nesupstituiran ili je supstituiran s 1 do 3 skupine C1-C6alkil;
svaki R12 je neovisno odabran između C1-C6alkila, hidroksila, halogena i C1-C6alkila supstituiranog s 1 do 3 -OH;
R13 je H ili C1-C6alkil;
R14 je H ili C1-C6alkil;
R15 je -NHC(=O)(CH2)mNHR5, -NHC(=O)(CH2)mN(R5)2, -NHC(=O)(CH2)mNH2, -NHC(=O)(CHR9)nR6, -NHC(=O)(CHR9)nN(R8)2, -NHC(=O)(CHR9)nNHR8, -NH(CHR9)nC(=O)N(R8)2, -NH(CHR9)nC(=O)R6, -NHR6, -NH2, -N(R5)2, -NHR8, -N(R6R8),-NH(C(R9)2)nR10, -NR9C(=O)OR11, -NH(CHR9)nR6, -N(R6)2, -N(CD3)2, -NH(CHR9)nOR9 ili -NHCH2(C(R9)2)nOR9;
svaki R16 je C1-C6alkil;
svaki R17 je neovisno odabran između H i C1-C6alkila;
svaki R18 je neovisno odabran između halogena, -CN, C1-C6alkoksi i C1-C6alkila;
m je 1, 2, 3, 4, 5 ili 6, i
n je 1, 2, 3, 4, 5 ili 6.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da ima strukturu s Formulom (I) ili Formulom (II), ili njihova farmaceutski prihvatljiva sol:
[image]
pri čemu su Y1, Y2, Y3, L, R1, R2 i RA kako je definirano u patentnom zahtjevu 1.
3. Spoj prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da spoj s Formulom (A) ili spoj s Formulom (I) ima strukturu Formule (Ia), Formule (Ib), Formule (Ic), Formule (Id), Formule (Ie), Formule (If), Formule (Ig), Formule (Ih), Formule (Ii), Formule (Ij) ili Formule (Ik), ili njihova farmaceutski prihvatljiva sol:
[image]
[image]
[image]
[image]
[image]
[image]
pri čemu su Y1, Y2, Y3, L, R1, R2, R3, R4, R13 i R14 kako je definirano u patentnom zahtjevu 1.
4. Spoj prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da spoj s Formulom (A) ili spoj s Formulom (II) ima strukturu Formule (IIa), Formule (IIb), Formule (IIc), Formule (IId), Formule (IIe), Formule (IIf), Formule (IIg), Formule (IIh), Formule (IIi), Formule (IIj) ili Formule (Ilk), ili njihova farmaceutski prihvatljiva sol:
[image]
[image]
[image]
[image]
[image]
[image]
pri čemu su Y1, Y2, Y3, L, R1, R2, R3, R4, R13 i R14 kako je definirano u patentnom zahtjevu 1.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4; ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
R1 je -NHC(=O)R6, -NHC(=O)(CH2)nR6, -NH(CH2)nC(=O)R6, -NHC(=O)(CH2)mNHR5, -NHC(=O)(CH2)mN(R5)2, -NHC(=O)(CHR9)mNHR5, -NHC(=O)(CH2)mNH2, -NHC(=O)(CH2)nOR9, -NHC(=O)OR9, -NH(CH2)mC(=O)N(R5)2, -NH(CHR9)mC(=O)R6, -NHR6, -NR5R6, -NH2, -N(R5)2, -NHR5, -NHR8, -NR9C(=O)OR11, -NH(CH2)nR6, -N(R6)2, -NHC(=O)(CH2)nN(CD3)2, -NH(CHR9)nCH2OR9, -NHCH2(CHR9)nOR9, -NH(CHR9)nOR9, -NR9(CH2)nOR9, -NHCH2(C(R9)2)nOR9, -OR9, -NR9C(=O)R5, -NR9C(=O)OR5, -NHS(=O)2R5, -NHC(=O)(CH2)nNR9C(=O)R5, ili -NHC(=O)(CH2)nNR9S(=O)2R5.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
R1 je -NHC(=O)R6, -NHC(=O)(CH2)nR6, -NH(CH2)nC(=O)R6, -NHC(=O)(CH2)mNHR5, -NHC(=O)(CH2)mN(R5)2, -NHC(=O)(CHR9)mNHR5, -NHC(=O)(CH2)mNH2, -NH(CH2)mC(=O)N(R5)2, -NH(CHR9)nC(=O)R6, -NHR6, -NH2, -N(R5)2, -NHR5, -NHR8, -NH(CHR9)nOR9 ili -NHCH2(C(R9)2)nOR9.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
R1 je -NHC(=O)R6, -NHC(=O)(CHR9)nR6, -NH(CHR9)nC(=O)R6 ili -NHR6.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
L je -CH2- ili -CH2CH2-;
Y1 je -CH2- ili -CH2CH2-;
Y2 je -CH2- ili -CH2CH2-;
Y3 je -CH2- ili -XCH2-;
X je -CH2- ili O;
R1 je -NH(CH2)nC(=O)R6, -NH(CH2)mC(=O)N(R5)2, -NH(CHR9)nC(=O)R6, -NH(CHR9)nC(=O)N(R8)2, -NH(CHR9)mC(=O)R6, -NH(C(R9)2)nR10, -NH(CH2)nR6, -NH(CHR9)nR6, -NH(CHR9)nCH2OR9, -NHCH2(CHR9)nOR9, -NH(CHR9)nOR9, -NR9(CH2)nOR9, ili -NHCH2(C(R9)2)nOR9;
R2 je H, C1-C6alkil ili C1-C6haloalkil;
R3 je H, C1-C6alkil ili -CD3;
R4 je H, NH2, C1-C6alkil ili halogen;
svaki R5 je neovisno C1-C6alkil, -CD3 ili -(CH2)nOR9;
R6 je C3-C6cikloalkil ili 4-6-eročlani heterocikloalkil koji ima 1 do 2 člana prstena neovisno odabrana između N, NH, NR16 i O koji je nesupstituiran ili je supstituiran s 1-2 skupine R12;
svaki R8 je neovisno odabran između C1-C6haloalkila, -(C(R9)2)nOR9 i C1-C6alkila supstituiranog s 1 do 3 -OH;
svaki R9 je neovisno odabran između H i C1-C6alkila;
R10 je C1-C6alkoksi ili C3-C6cikloalkil;
svaki R12 je neovisno odabran između C1-C6alkila, hidroksila, halogena i C1-C6alkila supstituiranog s 1 do 3 -OH;
R13 je H ili C1-C6alkil;
R14 je H ili C1-C6alkil;
svaki R16 je C1-C6alkil;
svaki R17 je neovisno H ili C1-C6alkil;
svaki R18 je neovisno halogen, -CN, C1-C6alkoksi ili C1-C6alkil;
m je 1, 2, 3, 4, 5 ili 6, i
n je 1, 2, 3, 4, 5 ili 6.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
L je -CH2- ili -CH2CH2-;
Y1 je -CH2- ili -CH2CH2-;
Y2 je -CH2- ili -CH2CH2-;
Y3 je -CH2- ili -XCH2-;
X je -CH2- ili O;
R1 je -NHR6, -NR5R6, -NH2, -N(R5)2, -NHR5, -NHR8, -N(R6R8) ili -N(R6)2;
R2 je H, C1-C6alkil ili C1-C6haloalkil;
R3 je H, C1-C6alkil ili -CD3;
R4 je H, NH2, C1-C6alkil ili halogen;
svaki R5 je neovisno C1-C6alkil, -CD3 ili -(CH2)nOR9;
R6 je C3-C6cikloalkil ili 4-6-eročlani heterocikloalkil koji ima 1 do 2 člana prstena neovisno odabrana između N, NH, NR16 i O koji je nesupstituiran ili je supstituiran s 1-2 skupine R12;
svaki R8 je neovisno odabran između C1-C6haloalkila, -(C(R9)2)nOR9 i C1-C6alkila supstituiranog s 1 do 3 -OH;
svaki R12 je neovisno odabran između C1-C6alkila, hidroksila, halogena i C1-C6alkila supstituiranog s 1 do 3 -OH;
R13 je H ili C1-C6alkil;
R14 je H ili C1-C6alkil;
svaki R16 je C1-C6alkil;
svaki R17 je neovisno H ili C1-C6alkil;
svaki R18 je neovisno halogen, -CN, C1-C6alkoksi ili C1-C6alkil;
m je 1, 2, 3, 4, 5 ili 6, i
n je 1, 2, 3, 4, 5 ili 6.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, naznačen time, da
R6 je nesupstituiran 4-6-eročlani heterocikloalkil koji ima 1 do 2 člana prstena neovisno odabrana između N, NH i O.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, naznačen time, da
R6 je ciklobutil, oksetanil, piperidinil, pirolidinil, morfolinil ili azetadinil.
12. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se bira iz niza koji sadrži:
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((3-metil-5-(6-metil-1H-pirazolo[3,4-b]piridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((3-metil-5-(2-metil-1,7-naftiridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((3-metil-5-(2-metil-7H-pirolo[2,3-d]pirimidin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((5-(1,6-dimetil-1H-pirolo[2,3-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)oksetan-3-amin;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(dimetilamino)acetamid;
(S)-N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin-3-karboksamid;
(R)-N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin-3-karboksamid;
6-(4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-oksa-6-azaspiro[3.3]heptan;
4-(1-((4-aminobiciklo[2.2.2]oktan-1-il)metil)-6,7-dihidro-1H-pirazolo[4,3-c]piridin-5(4H)-il)-1-metil-1H-pirazolo[3,4-d]pirimidin-6-amin;
4-(2-((4-aminobiciklo[2.2.2]oktan-1-il)metil)-6,7-dihidro-2H-pirazolo[4,3-c]piridin-5(4H)-il)-1-metil-1H-pirazolo[3,4-d]pirimidin-6-amin;
4-(1-((4-aminobiciklo[2.2.2]oktan-1-il)metil)-3-metil-6,7-dihidro-1H-pirazolo[4,3-c]piridin-5(4H)-il)-1-metil-1H-pirazolo[3,4-d]pirimidin-6-amin;
4-(2-((4-aminobiciklo[2.2.2]oktan-1-il)metil)-3-metil-6,7-dihidro-2H-pirazolo[4,3-c]piridin-5(4H)-il)-1-metil-1H-pirazolo[3,4-d]pirimidin-6-amin;
4-((5-(5-kloro-1-metil-1H-pirazolo[4,3-d]pirimidin-7-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
1,6-dimetil-4-(3-metil-1-((4-(pirolidin-1-il)biciklo[2.2.2]oktan-1-il)metil)-6,7-dihidro-1H-pirazolo[4,3-c]piridin-5(4H)-il)-1H-pirazolo[3,4-d]pirimidin;
1,3,5-trimetil-7-(3-metil-1-((4-(pirolidin-1-il)biciklo[2.2.2]oktan-1-il)metil)-6,7-dihidro-1H-pirazolo[4,3-c]piridin-5(4H)-il)-1H-pirazolo[4,3-d]pirimidin;
N-(2-metoksietil)-4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-d]pirimidin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin;
2-(etilamino)-N-(4-((3-metil-5-(6-metil-1H-pirazolo[3,4-d]pirimidin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)acetamid;
4-(4-((3-metil-5-(6-metil-1H-pirazolo[3,4-d]pirimidin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin;
2-(etilamino)-N-(4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)acetamid;
4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-(oksetan-3-ilmetil)biciklo[2.2.2]oktan-1-amin;
3-(dimetilamino)-N-(4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)propanamid;
4-(4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin;
4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
N-ciklobutil-4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
N,N-diciklobutil-4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
6-metil-4-(3-metil-1-((4-(piperidin-1-il)biciklo[2.2.2]oktan-1-il)metil)-6,7-dihidro-1H-pirazolo[4,3-c]piridin-5(4H)-il)-1H-pirazolo[3,4-d]pirimidin;
6-metil-4-(3-metil-1-((4-(pirolidin-1-il)biciklo[2.2.2]oktan-1-il)metil)-6,7-dihidro-1H-pirazolo[4,3-c]piridin-5(4H)-il)-1H-pirazolo[3,4-d]pirimidin;
(3-(((4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)amino)metil)oksetan-3-il)metanol;
N-(4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)azetidin-3-karboksamid;
(S)-N-(4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin-3-karboksamid;
(S)-N-(4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin-2-karboksamid;
(R)-N-(4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin-3-karboksamid;
(R)-N-(4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin-2-karboksamid;
3,6-dimetil-4-(3-metil-1-((4-morfolinobiciklo[2.2.2]oktan-1-il)metil)-6,7-dihidro-1H-pirazolo[4,3-c]piridin-5(4H)-il)izoksazolo[5,4-d]pirimidin;
1,3,5-trimetil-7-(3-metil-1-((4-(piperidin-1-il)biciklo[2.2.2]oktan-1-il)metil)-6,7-dihidro-1H-pirazolo[4,3-c]piridin-5(4H)-il)-1H-pirazolo[4,3-d]pirimidin;
1,6-dimetil-4-(3-metil-1-((4-(piperidin-1-il)biciklo[2.2.2]oktan-1-il)metil)-6,7-dihidro-1H-pirazolo[4,3-c]piridin-5(4H)-il)-1H-pirazolo[3,4-d]pirimidin;
4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N,N-bis(trideuterometil)biciklo[2.2.2]oktan-1-amin;
4-((3-metil-5-(1H-pirazolo[3,4-b]piridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((3-metil-5-(1H-pirazolo[3,4-b]piridin-4-il)-4,5,6,7-tetrahidro-2H-pirazolo[4,3-c]piridin-2-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N,N-dimetilbiciklo[2.2.2]oktan-1-amin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.1]heptan-1-amin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-(trifluorometil)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-ol;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)acetamid;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)metansulfonamid;
terc-butil (4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)(metil)karbamat;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-metilbiciklo[2.2.2]oktan-1-amin;
1-metilciklopropil (4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)karbamat;
3-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-2H-pirazolo[4,3-c]piridin-2-il)metil)biciklo[1.1.1]pentan-1-amin;
4-((5-(1-(4-metoksibenzil)-6-metil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
N-ciklobutil-4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-izopropilbiciklo[2.2.2]oktan-1-amin;
2-((4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)amino)propan-1-ol;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-etilbiciklo[2.2.2]oktan-1-amin;
5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-1-((4-(pirolidin-1-il)biciklo[2.2.2]oktan-1-il)metil)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin;
4-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-7,7-dimetil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
N-(2,2-difluoroetil)-4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
-((3-metil-5-(2-metilquinolin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((3-metil-5-(2-fenilpiridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
1-((4-(azetidin-1-il)biciklo[2.2.2]oktan-1-il)metil)-5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-7,7-dimetil-4,5,6,7-tetrahidro-2H-pirazolo[4,3-c]piridin-2-il)metil)biciklo[2.2.2]oktan-1-amin;
4-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)tiomorfolin 1,1-dioksid;
5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-1-((4-(piperidin-1-il)biciklo[2.2.2]oktan-1-il)metil)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin;
1-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)azetidin-3-ol;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-(2-metoksietil)biciklo[2.2.2]oktan-1-amin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N,N-bis(2-metoksietil)biciklo[2.2.2]oktan-1-amin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-(2-etoksietil)biciklo[2.2.2]oktan-1-amin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N,N-bis(2-etoksietil)biciklo[2.2.2]oktan-1-amin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-(2-metoksietil)-N-metilbiciklo[2.2.2]oktan-1-amin;
(3S,4R)-1-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)pirolidin-3,4-diol;
(S)-1-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)pirolidin-3-ol;
2-((4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)amino)-N,N-dimetilacetamid;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-N-metiloksetan-3-amin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-izopropil-N-metilbiciklo[2.2.2]oktan-1-amin;
N-ciklobutil-4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-metilbiciklo[2.2.2]oktan-1-amin;
(3S,4S)-1-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)pirolidin-3,4-diol;
1-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-2-oksabiciklo[2.2.2]oktan-4-amin;
5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-1-((4-(pirolidin-1-il)-2-oksabiciklo[2.2.2]oktan-1-il)metil)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin;
4-((5-(6-(4-fluorofenil)-1-metil-1H-pirazolo[3,4-d]pirimidin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-(4-(1-((4-aminobiciklo[2.2.2]oktan-1-il)metil)-3-metil-6,7-dihidro-1H-pirazolo[4,3-c]piridin-5(4H)-il)piridin-2-il)benzonitril;
3-metil-5-(2-fenilpiridin-4-il)-1-((4-(pirolidin-1-il)biciklo[2.2.2]oktan-1-il)metil)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin;
2-metil-4-(3-metil-1-((4-(pirolidin-1-il)biciklo[2.2.2]oktan-1-il)metil)-6,7-dihidro-1H-pirazolo[4,3-c]piridin-5(4H)-il)-1,7-naftiridin;
4-((5-(2-(4-fluorofenil)piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((5-(2-(2-fluoro-4-metilfenil)piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((5-(2-(4-metoksifenil)piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((3-metil-5-(2-(p-tolil)piridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-(2-(5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)etil)biciklo[2.2.2]oktan-1-amin;
4-((5-(2,8-dimetil-1,7-naftiridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((3-metil-5-(2-metil-6-fenilpiridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-((5-([2,2'-bipiridin]-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-1-((4-(piperidin-1-il)-2-oksabiciklo[2.2.2]oktan-1-il)metil)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-(1-metoksipropan-2-il)biciklo[2.2.2]oktan-1-amin;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-etil-N-metilbiciklo[2.2.2]oktan-1-amin;
1-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N,N-dimetil-2-oksabiciklo[2.2.2]oktan-4-amin;
2-((4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)amino)-1-(piperidin-1-il)etanon;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(pirolidin-1-il)acetamid;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-(2-metoksi-2-metilpropil)biciklo[2.2.2]oktan-1-amin;
1-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-N-(2-metoksietil)-2-oksabiciklo[2.2.2]oktan-4-amin;
4-((5-(2-kloro-5,7-dihidrofuro[3,4-d]pirimidin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
4-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-1-metilpiperazin-2-on;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-3-(dimetilamino)propanamid;
2-((4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)amino)-1-(pirolidin-1-il)etanon;
(R)-4-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-metilmorfolin;
1-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-4-metilpiperazin-2-on;
(S)-4-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-metilmorfolin;
(2S,6R)-4-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2,6-dimetilmorfolin;
(2S,6S)-4-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2,6-dimetilmorfolin;
N-(ciklobutilmetil)-1-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-2-oksabiciklo[2.2.2]oktan-4-amin;
(2R,6R)-4-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2,6-dimetilmorfolin;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(etilamino)acetamid;
3-amino-N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)propanamid;
6-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-oksa-6-azaspiro[3.3]heptan;
(R)-N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(metilamino)propanamid;
(S)-N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(metilamino)propanamid;
1-((4-(1H-imidazol-1-il)biciklo[2.2.2]oktan-1-il)metil)-5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin;
(1R,5S)-3-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-8-oksa-3-azabiciklo[3.2.1]oktan;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(metilamino)acetamid;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-4-metilmorfolin-3-karboksamid;
1-((4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)amino)-2-metilpropan-2-ol;
2-(etilamino)-N-(4-((3-metil-5-(5-metil-1H-pirazolo[4,3-b]piridin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)acetamid;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin-2-karboksamid;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-3-(etilamino)propanamid;
N-etil-4-((3-metil-5-(2-fenilpiridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
(S)-4-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-3-metilmorfolin;
(R)-4-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-3-metilmorfolin;
N-(2-metoksietil)-4-((3-metil-5-(2-fenilpiridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)azetidin-3-karboksamid;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(etil(metil)amino)acetamid;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(3-fluoroazetidin-1-il)acetamid;
2-(bis(trideuterometil)amino)-N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)acetamid;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-hidroksiacetamid;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(3-hidroksiazetidin-1-il)acetamid;
(3-(((4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)amino)metil)oksetan-3-il)metanol;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(N-metilmetilsulfonamido)acetamid;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(N-metilacetamido)acetamid
4-((3-metil-5-(6-metil-1-(trideuterometil)-1H-pirazolo[3,4-b]piridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
(S)-N-(4-((5-(1-etil-6-metil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin-3-karboksamid;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-3-(metilamino)propanamid;
N-ciklobutil-1-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)-2-oksabiciklo[2.2.2]oktan-4-amin;
N-ciklobutil-4-((3-metil-5-(2-fenilpiridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin;
terc-butil (4-((5-(1-etil-6-metil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)karbamat;
terc-butil (4-((3-metil-5-(2-metil-7H-pirolo[2,3-d]pirimidin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)karbamat;
terc-butil (4-((3-metil-5-(2-metil-1,7-naftiridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)karbamat;
terc-butil (4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.1]heptan-1-il)karbamat;
4-((5-(1,6-dimetil-1H-pirazolo[3,4-d]pirimidin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin, i
4-((5-(1-etil-6-metil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-amin.
13. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se bira iz niza koji sadrži:
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)oksetan-3-amin;
N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-(dimetilamino)acetamid;
(S)-N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin-3-karboksamid;
(R)-N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)morfolin-3-karboksamid, i
6-(4-((3-metil-5-(1,3,5-trimetil-1H-pirazolo[4,3-d]pirimidin-7-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciklo[2.2.2]oktan-1-il)-2-oksa-6-azaspiro[3.3]heptan.
14. Farmaceutski pripravak, naznačen time, da sadrži terapijski učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva 1 do 13, ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za upotrebu u liječenju autoimune bolesti.
16. Spoj za upotrebu prema patentnom zahtjevu 15, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je autoimuna bolest sistemski eritemski lupus, kožni lupus, diskoidni lupus, miješana bolest vezivnog tkiva, primarna bilijarna ciroza, imunološka trombocitopenija purpura, gnojni hidradenitis, dermatomiozitis, polimiozitis, Sjögrenov sindrom, artritis, reumatoidni artritis ili psorijaza.
17. Kombinacija, naznačena time, da sadrži terapijski učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva 1 do 13, ili njegovu farmaceutski prihvatljivu sol, i jedno ili više dodatnih terapijskih sredstava, pri čemu je dodatno terapijsko sredstvo neovisno odabrano između protuupalnih sredstava, imunomodulacijskih sredstava, imunosupresivnih sredstava, citokina, nesteroidnih protuupalnih lijekova (NSAID), antimalarijskih spojeva, antireumatskih spojeva, inhibitora faktora aktivacije B-stanica (BAFF), inhibitora stimulatora B-limfocita (BLyS), i steroidnih hormona.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662385726P | 2016-09-09 | 2016-09-09 | |
PCT/IB2017/055375 WO2018047081A1 (en) | 2016-09-09 | 2017-09-06 | Compounds and compositions as inhibitors of endosomal toll-like receptors |
EP17777966.7A EP3510033B1 (en) | 2016-09-09 | 2017-09-06 | Compounds and compositions as inhibitors of endosomal toll-like receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220144T1 true HRP20220144T1 (hr) | 2022-04-15 |
Family
ID=60001955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220144TT HRP20220144T1 (hr) | 2016-09-09 | 2017-09-06 | Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora |
Country Status (36)
Country | Link |
---|---|
US (2) | US10954233B2 (hr) |
EP (2) | EP3510033B1 (hr) |
JP (1) | JP6779371B2 (hr) |
KR (2) | KR20190039809A (hr) |
CN (2) | CN109641899B (hr) |
AU (1) | AU2017323584C1 (hr) |
BR (1) | BR112019004597A2 (hr) |
CA (1) | CA3031585A1 (hr) |
CL (1) | CL2019000588A1 (hr) |
CO (1) | CO2019003397A2 (hr) |
CR (1) | CR20190119A (hr) |
CU (1) | CU24526B1 (hr) |
CY (1) | CY1125007T1 (hr) |
DK (1) | DK3510033T3 (hr) |
DO (1) | DOP2019000055A (hr) |
EA (1) | EA036880B1 (hr) |
EC (1) | ECSP19024046A (hr) |
ES (1) | ES2905981T3 (hr) |
HR (1) | HRP20220144T1 (hr) |
HU (1) | HUE057254T2 (hr) |
IL (1) | IL265159B (hr) |
JO (1) | JOP20190041B1 (hr) |
LT (1) | LT3510033T (hr) |
MA (1) | MA46196A (hr) |
MX (1) | MX2019002797A (hr) |
MY (1) | MY194813A (hr) |
PE (1) | PE20190732A1 (hr) |
PH (1) | PH12019500161A1 (hr) |
PL (1) | PL3510033T3 (hr) |
PT (1) | PT3510033T (hr) |
RS (1) | RS62913B1 (hr) |
RU (1) | RU2759678C2 (hr) |
SG (1) | SG11201900482SA (hr) |
SI (1) | SI3510033T1 (hr) |
WO (1) | WO2018047081A1 (hr) |
ZA (1) | ZA201900227B (hr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3929196T (pt) | 2013-09-24 | 2023-09-11 | Fujifilm Corp | Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal |
CN115317603A (zh) | 2016-07-07 | 2022-11-11 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
BR112019004597A2 (pt) | 2016-09-09 | 2019-06-11 | Novartis Ag | compostos e composições como inibidores de receptores endossomais do tipo toll |
EP3526323B1 (en) | 2016-10-14 | 2023-03-29 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
CA3084582A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2019123294A2 (en) | 2017-12-22 | 2019-06-27 | Novartis Ag | Novel uses of pyrazolo piperidine derivatives |
CN111699187A (zh) | 2018-02-12 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的砜化合物和衍生物 |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
KR20200140867A (ko) | 2018-04-06 | 2020-12-16 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
WO2019220390A1 (en) * | 2018-05-18 | 2019-11-21 | Novartis Ag | Crystalline forms of a tlr7/tlr8 inhibitor |
TW202016105A (zh) | 2018-06-12 | 2020-05-01 | 瑞士商赫孚孟拉羅股份公司 | 用於治療自體免疫疾病的新穎雜芳基雜環基化合物 |
JP7366994B2 (ja) | 2018-07-23 | 2023-10-23 | エフ. ホフマン-ラ ロシュ アーゲー | 自己免疫疾患治療用の新規ピペラジン化合物 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
JP7233809B2 (ja) | 2018-09-04 | 2023-03-07 | エフ. ホフマン-ラ ロシュ アーゲー | 自己免疫疾患の処置のためのベンゾチアゾール化合物 |
WO2020048595A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel cyclic amidine compounds for the treatment of autoimmune disease |
US20210253575A1 (en) * | 2018-09-07 | 2021-08-19 | Hoffmann-La Roche Inc. | Pyrrolidine amine compounds for the treatment of autoimmune disease |
CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
KR102650496B1 (ko) | 2018-10-31 | 2024-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물 |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 2’3’-環状ジヌクレオチドおよびそのプロドラッグ |
KR20220004634A (ko) | 2019-03-15 | 2022-01-11 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | Her2를 표적으로 하는 면역접합체 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2020240272A1 (en) * | 2019-05-31 | 2020-12-03 | Dr.Reddy's Institute Of Life Sciences | Preparation of novel 1 h-pyrazolo[4,3-d]pyrimidines, their compositions, synthesis and methods of using them for treating tuberculosis |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
BR112022005687A2 (pt) | 2019-09-30 | 2022-06-21 | Gilead Sciences Inc | Vacinas contra o hbv e métodos para tratar o hbv |
US20230031465A1 (en) | 2019-12-06 | 2023-02-02 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
KR20220156884A (ko) | 2020-03-20 | 2022-11-28 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
WO2022013136A1 (en) | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
JP2024513945A (ja) | 2021-04-16 | 2024-03-27 | ギリアード サイエンシーズ, インコーポレイテッド | チオノピロール化合物 |
JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | TLR8調節化合物と抗HBV siRNA治療薬との組合せ |
EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023046806A1 (en) | 2021-09-24 | 2023-03-30 | F. Hoffmann-La Roche Ag | Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease |
TW202337443A (zh) | 2022-01-11 | 2023-10-01 | 瑞士商諾華公司 | 使用tlr7/8拮抗劑治療sjogren氏症候群或混合性結締組織病之方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03001169A (es) | 2000-08-10 | 2003-06-30 | Pharmacia Italia Spa | Biciclo-pirazoles activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos. |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US20070037790A1 (en) | 2003-03-11 | 2007-02-15 | Francesca Abrate | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
AU2005302697B2 (en) | 2004-10-27 | 2012-09-13 | Janssen Pharmaceutica, N.V. | Tetrahydro pyridinyl pyrazole cannabinoid modulators |
US20070093515A1 (en) * | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
WO2007034817A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
WO2007123953A2 (en) | 2006-04-19 | 2007-11-01 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
CN101668759A (zh) | 2007-05-04 | 2010-03-10 | 百时美施贵宝公司 | [6,5]-双环gpr119g蛋白-偶合受体激动剂 |
NZ585063A (en) * | 2007-11-02 | 2012-05-25 | Vertex Pharma | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
US8524702B2 (en) | 2009-08-18 | 2013-09-03 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
WO2011049825A1 (en) * | 2009-10-22 | 2011-04-28 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
WO2012154608A1 (en) | 2011-05-06 | 2012-11-15 | Intellikine, Llc | Reactive mtor and pi3 kinase inhibitors and uses thereof |
CA2840060A1 (en) | 2011-06-27 | 2013-01-03 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
MY169159A (en) | 2012-02-08 | 2019-02-19 | Janssen R&D Ireland | Piperidino-pyrimidine derivatives for the treatment of viral infections |
JO3407B1 (ar) * | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
JPWO2014034719A1 (ja) | 2012-08-29 | 2016-08-08 | 興和株式会社 | Tlr阻害作用を有するキノリン誘導体 |
ES2670513T3 (es) | 2012-10-10 | 2018-05-30 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades |
WO2014111496A1 (en) | 2013-01-18 | 2014-07-24 | F. Hoffmann-La Roche Ag | 3-substituted pyrazoles and use as dlk inhibitors |
SG11201506800YA (en) | 2013-03-14 | 2015-09-29 | Bristol Myers Squibb Co | Bicyclo [2.2.2] acid gpr120 modulators |
WO2014177977A1 (en) | 2013-05-02 | 2014-11-06 | Pfizer Inc. | Imidazo-triazine derivatives as pde10 inhibitors |
US10471139B2 (en) * | 2013-08-15 | 2019-11-12 | The University Of Kansas | Toll-like receptor agonists |
WO2015024021A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | Antibacterial compounds |
WO2015024120A1 (en) | 2013-08-19 | 2015-02-26 | Queen's University At Kingston | Carbene functionalized composite materials |
MX2016002238A (es) | 2013-08-22 | 2016-05-31 | Hoffmann La Roche | Alcoholes de alquilino y metodos de uso. |
WO2015036044A1 (en) | 2013-09-13 | 2015-03-19 | Telormedix Sa | Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood |
JP6483666B2 (ja) | 2013-10-14 | 2019-03-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的に置換されたキノリン化合物 |
PT3057964T (pt) * | 2013-10-14 | 2020-02-25 | Eisai R&D Man Co Ltd | Compostos de quinolina seletivamente substituídos |
WO2016004272A1 (en) * | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
LT3190113T (lt) | 2014-08-15 | 2021-08-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai |
WO2016097918A1 (en) * | 2014-12-18 | 2016-06-23 | Pfizer Inc. | Pyrimidine and triazine derivatives and their use as axl inhibitors |
CA2972434A1 (en) | 2014-12-30 | 2016-07-07 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis b infections |
WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
JP6826993B2 (ja) | 2015-03-12 | 2021-02-10 | ノバルティス アーゲー | 複素環化合物およびその使用方法 |
IL261606B (en) | 2016-03-16 | 2022-09-01 | Kura Oncology Inc | Inhibitors of converted menin-mll and methods of use |
BR112019004597A2 (pt) | 2016-09-09 | 2019-06-11 | Novartis Ag | compostos e composições como inibidores de receptores endossomais do tipo toll |
-
2017
- 2017-09-06 BR BR112019004597A patent/BR112019004597A2/pt active Search and Examination
- 2017-09-06 PL PL17777966T patent/PL3510033T3/pl unknown
- 2017-09-06 CU CU2019000018A patent/CU24526B1/es unknown
- 2017-09-06 EA EA201990657A patent/EA036880B1/ru not_active IP Right Cessation
- 2017-09-06 MA MA046196A patent/MA46196A/fr unknown
- 2017-09-06 WO PCT/IB2017/055375 patent/WO2018047081A1/en unknown
- 2017-09-06 US US16/330,820 patent/US10954233B2/en active Active
- 2017-09-06 JO JOP/2019/0041A patent/JOP20190041B1/ar active
- 2017-09-06 SI SI201731065T patent/SI3510033T1/sl unknown
- 2017-09-06 JP JP2019513008A patent/JP6779371B2/ja active Active
- 2017-09-06 CA CA3031585A patent/CA3031585A1/en active Pending
- 2017-09-06 HU HUE17777966A patent/HUE057254T2/hu unknown
- 2017-09-06 DK DK17777966.7T patent/DK3510033T3/da active
- 2017-09-06 KR KR1020197008484A patent/KR20190039809A/ko not_active IP Right Cessation
- 2017-09-06 AU AU2017323584A patent/AU2017323584C1/en active Active
- 2017-09-06 CN CN201780053304.6A patent/CN109641899B/zh active Active
- 2017-09-06 MY MYPI2019000071A patent/MY194813A/en unknown
- 2017-09-06 HR HRP20220144TT patent/HRP20220144T1/hr unknown
- 2017-09-06 CR CR20190119A patent/CR20190119A/es unknown
- 2017-09-06 EP EP17777966.7A patent/EP3510033B1/en active Active
- 2017-09-06 CN CN202210863391.4A patent/CN115215886A/zh active Pending
- 2017-09-06 PT PT177779667T patent/PT3510033T/pt unknown
- 2017-09-06 KR KR1020217018684A patent/KR102411532B1/ko active IP Right Grant
- 2017-09-06 EP EP21208454.5A patent/EP4059934A1/en active Pending
- 2017-09-06 LT LTEPPCT/IB2017/055375T patent/LT3510033T/lt unknown
- 2017-09-06 RS RS20220087A patent/RS62913B1/sr unknown
- 2017-09-06 ES ES17777966T patent/ES2905981T3/es active Active
- 2017-09-06 RU RU2019110157A patent/RU2759678C2/ru active
- 2017-09-06 PE PE2019000478A patent/PE20190732A1/es unknown
- 2017-09-06 SG SG11201900482SA patent/SG11201900482SA/en unknown
- 2017-09-06 MX MX2019002797A patent/MX2019002797A/es unknown
-
2019
- 2019-01-14 ZA ZA201900227A patent/ZA201900227B/en unknown
- 2019-01-22 PH PH12019500161A patent/PH12019500161A1/en unknown
- 2019-03-04 IL IL265159A patent/IL265159B/en unknown
- 2019-03-06 DO DO2019000055A patent/DOP2019000055A/es unknown
- 2019-03-08 CL CL2019000588A patent/CL2019000588A1/es unknown
- 2019-04-05 EC ECSENADI201924046A patent/ECSP19024046A/es unknown
- 2019-04-05 CO CONC2019/0003397A patent/CO2019003397A2/es unknown
-
2020
- 2020-12-16 US US17/124,346 patent/US20210101902A1/en active Pending
-
2022
- 2022-02-22 CY CY20221100153T patent/CY1125007T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220144T1 (hr) | Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora | |
RU2443706C2 (ru) | Фармацевтические соединения | |
RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
RU2011116447A (ru) | Модуляторы амилоида бета | |
HRP20180080T1 (hr) | Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze | |
RU2016111675A (ru) | Соединения биарилацетамида и способы их применения | |
UY37925A (es) | Formas cristalinas | |
JP2016504363A5 (hr) | ||
HRP20190748T1 (hr) | Derivati policikličkog amida kao inhibitori cdk9 | |
SI2945632T1 (en) | HETEROBICYL-SUBSTITUTED- (1,2,4) TRIAZOLO (1,5-C) KINAZOLIN-5-AMIN COMPOUNDS SUITABLE FOR TREATMENT AND PREVENTION OF THE EMISSION OF THE CENTRAL LIVING SYSTEM | |
HRP20170103T1 (hr) | Triazolopiridazini kao modulatori tirozin kinaze | |
HRP20120105T1 (hr) | Aminoheterociklički spojevi | |
AR065556A1 (es) | Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida | |
RU2016140338A (ru) | Азаспиро производные в качестве антагонистов trpm8 | |
RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
JP2011500774A5 (hr) | ||
RU2012136907A (ru) | Модуляторы гамма-секретазы | |
HRP20121069T1 (hr) | Supstituirani derivati amida kao inhibitori protein kinaze | |
PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
HRP20211483T1 (hr) | Derivati 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ola i povezani spojevi kao inhibitori prs za liječenje npr. raka | |
CY1109263T1 (el) | Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine | |
HRP20230120T1 (hr) | Inhibitori bcl6 | |
IL275489B1 (en) | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
WO2023018810A1 (en) | Heterocyclic compounds and methods of use | |
EP4329888A1 (en) | 2-aminobenzothiazole compounds and methods of use thereof |